vice president of programs, public affairs, and research at Lung Health Foundation.

New Lung Cancer Risk Calculator Streamlines Screening Eligibility, With Jessica Moffatt, PhD

The Lung Health Foundation has introduced a simplified 

 calculator designed to help patients and clinicians better understand eligibility for organized screening programs across Canada. Built on the validated PLCOm2012 risk prediction model, the online tool translates a previously spreadsheet-based calculator into a plain-language, 10-question interface that generates a 6-year lung cancer risk estimate in 2 – 3 minutes.

Lung cancer screening differs from other cancer screening programs in that it is risk-based rather than population-based. Patients must meet age criteria and have a sufficient smoking history before undergoing a formal risk assessment through a provincial program. That multi-step structure can create uncertainty in primary care settings, particularly during time-limited visits.

, investigator Jessica Moffatt, PhD, vice president of programs, public affairs, and research at Lung Health Foundation, emphasized that the calculator does not diagnose cancer and does not determine formal screening eligibility.

“The only official risk assessment result is the risk assessment result that's conducted with the screening program,” Moffatt said. “What this can do is this can be supplemental to that clinician-patient conversation to really help facilitate that informed decision-making process between the clinician and the patient to help the clinician understand, should I make the referral for screening? Once that referral is made, the official risk assessment is conducted. This is just a tool to help the clinician understand, is my patient actually eligible, or may they be eligible for lung cancer screening?”

The calculator produces a downloadable PDF summary without jargon, allowing patients to bring their responses into an appointment. Developers said this feature was designed with primary care workflows in mind, enabling clinicians to review key inputs, such as age, smoking exposure, comorbidities, and prior cancer history, without navigating a complex risk model during the visit.

The tool may also benefit individuals without a regular primary care provider. In some provinces, patients can self-refer to lung cancer screening programs. A preliminary risk estimate may help them decide whether contacting a screening site is warranted.

The PLCOm2012 model is structured to balance benefit and harm. Low-dose CT screening carries risks, including false positives and downstream procedures. By anchoring the calculator in an established risk framework, the Lung Health Foundation aims to support appropriate screening conversations while reinforcing that patients with symptoms, such as persistent cough, hemoptysis, or unexplained weight loss, require diagnostic evaluation rather than screening.

With many lung cancers still diagnosed at advanced stages, the Lung Health Foundation positions the calculator as an entry point to informed discussions, not a substitute for clinical judgment.

“We recognize how busy primary care providers are, and this is a tool that can help primary care providers, in a very streamlined way, have that discussion with their patient that lung cancer screening may be right for them,” Moffatt said. “It's convenient for the public, but it's also convenient for clinicians.”

‘Think Mortgage Calculator, But for Lung Cancer Risk’: A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point. GlobeNewswire. Published on February 4, 2026. Accessed on February 12, 2026. 

https://finance.yahoo.com/news/think-mortgage-calculator-lung-cancer-123000493.html?guccounter=1&guce_referrer=aHR0cHM6Ly9zdGF0aWNzLnRlYW1zLmNkbi5vZmZpY2UubmV0Lw&guce_referrer_sig=AQAAANFnUl3Oz4FMn8kNg43vqehf_7SF1nUmh0k1LLaCpbMdC9_T-6vswljrh6fwLmRxxEGMwz-0dnFQjGKKfqJJWi0oQETyZDsfkBeYGnzfUqTpyxdDpQumjFy3NQ7FXywWocCd8t8GXlRUV3iH2g3ONrsSgg6yIeNYhnHt2F9RSZuO

Videos

The free, user-friendly calculator provides a 6-year lung cancer risk estimate to help patients and clinicians assess screening eligibility.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lung Cancer

Tool Predicts a 6-Year-Risk Lung Cancer Risk in Minutes, With Jessica Moffatt, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

New research is shedding light on healthcare provider (HCP) perceptions and prescribing patterns of pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI).

The real-world survey findings suggest HCPs consider multiple factors when determining an appropriate PERT choice and indicate prescribing a variety of PERT products, influenced most heavily by abdominal and bowel symptom control, affordability, and formulary or insurance coverage.

A condition in which the small intestine cannot digest food completely because of problems with digestive enzymes from the pancreas, EPI management relies heavily on PERT to substitute for the missing digestive enzymes. PERT products like Creon, Zenpep, Pancreaze, Viokace, and Pertzye are all composed of pancrelipase but differ in formulation-specific attributes and access/coverage considerations.

“HCPs must consider multiple factors when selecting a PERT product for a given patient,” Jodie Barkin, MD, an associate professor of Clinical Medicine at the University of Miami Miller School of Medicine, and colleagues wrote.1 “Understanding their decision-making process and preferences for different PERT products can offer valuable insights into real-world clinical practice and support optimal care for patients with EPI. However, the current literature lacks comprehensive real-world studies describing how HCPs in the United States manage PERT therapy and perceive different PERT products.”

To assess real-world EPI management practice and HCP perceptions of PERT products in the United States, investigators carried out an online survey with HCPs who had treated patients with EPI for ≥ 3 years and prescribed PERT products to ≥ 10 patients over a 12-month period.

The survey collected de-identified data on HCP characteristics, prescribing patterns, and perceptions of PERT products across the domains of efficacy, convenience, and access. Of note, survey responses were self-reported by HCPs. No patient-level data were collected; all responses were based on HCP recollection, including aggregated patient characteristics using questions that asked respondents to report the characteristics of their patients.

A total of 250 HCPs were surveyed, including 124 specialists, 95 generalists, and 31 advanced practice providers. HCPs managed a median of 30 patients with EPI on PERT in the 12 months preceding the survey.

Results showed the most commonly prescribed PERT products were Creon (84.0%), Zenpep (60.4%), and Pancreaze (59.2%), with fewer HCPs prescribing Viokace (27.2%) and Pertzye (16.0%). Specific factors considered in prescribing decisions included improvement in abdominal and bowel symptoms (83.6%), affordability (72.4%), and formulary/insurance coverage (72.0%).

Investigators noted a significantly greater proportion of HCPs reported favorable perceptions of Creon over other PERT products.

Perceptions of formulary/insurance coverage across PERT products varied, with 8.0–56.0% of HCPs agreeing or strongly agreeing that a prescribed product had good coverage.

Investigators pointed out these findings were generally consistent across different provider types.

“This US-based survey study offered valuable insights into HCPs considerations when managing patients with EPI using PERT products, as well as their perceptions of individual products,” investigators concluded.1 “These findings may help to inform decision-making by clinicians and healthcare payers that could ultimately support improved quality and continuity of care for EPI patients. Various factors may contribute to barriers in treatment access and should be addressed to ensure equitable and timely access to PERT.”

Ashkar M, Geremia J, Baldwin Z, et al. Prescribing Patterns and Perceptions of Pancreatic Enzyme Replacement Therapy among Healthcare Providers: A Prospective United States Healthcare Providers Survey. 

. Published online January 12, 2026. doi:10.1007/s12325-025-03454-7

NIDDK. Exocrine Pancreatic Insufficiency (EPI). Accessed February 12, 2026. 

https://www.niddk.nih.gov/health-information/digestive-diseases/exocrine-pancreatic-insufficiency/definition-facts

Cleveland Clinic. Exocrine Pancreatic Insufficiency (EPI). Accessed February 12, 2026. 

https://my.clevelandclinic.org/health/diseases/21577-exocrine-pancreatic-insufficiency-epi

Articles

US healthcare providers managing exocrine pancreatic insufficiency report that pancreatic enzyme replacement therapy selection is driven primarily by abdominal and bowel symptom control, affordability, and payer/formulary constraints. In a self-reported online survey of 250 clinicians with established EPI experience, Creon, Zenpep, and Pancreaze were most commonly prescribed, while Viokace and Pertzye were used less frequently. Favorability ratings were highest for Creon versus other products. Perceived insurance coverage varied widely across agents, suggesting access remains a major determinant of continuity and equity in therapy.

Survey findings highlight abdominal and bowel symptom control, affordability, and formulary or insurance coverage as factors driving perceptions and prescribing patterns of PERT.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Real-World Prescribing Patterns of PERT in Exocrine Pancreatic Insufficiency

Mark Kaufmann, MD, is a clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City.

Strategies on Maximizing Billing Effectiveness for Clinicians, With Mark Kaufmann, MD

The world of billing effectiveness among clinicians in 

 can be daunting for some, as healthcare coding, billing, and related impacts on the financial stability of practices are ever-changing in the field of medicine.

A session on this topic was presented at the 

 by Mark Kaufmann, MD, a clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City. Kaufmann spoke on-site at the conference with 

 regarding this talk and its biggest highlights for clinicians in dermatology who want to improve their billing effectiveness.

“I think one of the more important things that I discussed was really where we are and how we got here, and I think it's really important…because we're living in an environment of decreasing reimbursements and increasing costs,” Kaufmann expressed. “In order to keep our doors open, we need to think about efficiencies.”

Kaufmann pointed to the importance of implementing the entire fee schedule, rather than only the 20 or more codes used on a daily basis. He also stressed the value of considering alternative revenue streams for the medical office. Over the previous 25 years, Kaufmann noted, the reimbursement has been effectively decreasing.

“The Congress came out last year and said they were giving us a two-and-a-half percent upwards correction, and that's true, but even when you take that into account, we're still not just lower than we were 25 years ago,” Kaufmann said. “We're lower than we were three years ago, and so effectively, we're being cut every year, even when the buzz is that we're getting increases.”

Later, Kaufmann highlighted efficiencies being improved through artificial intelligence (AI) scribes. Thanks to AI scribes, Kaufmann described notes as improved, along with coding and compliance.

The quotes used in Kaufmann’s interview video were edited for the purposes of clarity.

Kaufmann has previously disclosed serving as a consultant for companies such as Apogee Therapeutics, Avita Medical, and Biofrontera, and he has held a position on the medical advisory board for Modernizing Medicine, Inc.

Kaufmann M, Siegel D. How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Burks K, Shields J, Flesher S, et al. A systematic review of outpatient billing practices. SAGE Open Med. 2022 May 23;10:20503121221099021. 

Mark Kaufmann, MD, speaks on maximizing your billing effectiveness in the era of dwindling reimbursements and ICD-10.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Zobair Younossi, MD, MPH, is chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System.

Diagnostic Performance of NITs Across MASLD Subgroups, With Zobair Younossi, MD

As metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise globally, the need for accurate, accessible risk stratification has never been greater. Historically, clinicians have relied on liver biopsy to identify the subgroup of patients with metabolic dysfunction–associated steatohepatitis (MASH) at the greatest risk for progression to cirrhosis, liver cancer, and liver-related mortality.

Because biopsy is invasive, costly, and not without risk, the field of hepatology has grown increasingly reluctant to rely on it for widespread screening and longitudinal monitoring. As Zobair Younossi, MD, professor and chairman of the Global NASH Council, explains in an interview with 

, the past decade has been defined by efforts to develop noninvasive alternatives that can match biopsy not only in staging accuracy but also in predicting long-term outcomes.

“NITs were first established on a liver biopsy to see if they're accurately predicting the stage that we want to look for,” he explained. “More recently, there is also data to suggest that these NITs predict outcome as well as liver biopsy, and maybe sometimes even better than a liver biopsy, which makes them ideal for clinical use and also for use in clinical trials.”

Specifically, Younossi references 3 main categories of noninvasive tests:

Imaging modalities like VCTE, shear wave elastography, and MRE

He additionally describes combination tests leveraging combined clinical data from existing NITs, including the FAST score, AGILE 3, and AGILE 4.

Younossi’s research, a trio of sequentially published papers, has explored how NITs perform across regions, how well they predict liver-related outcomes compared with biopsy, and how their accuracy varies in key subgroups.

Of note, while all NITs demonstrated outcome prediction comparable to, and in some cases better than, biopsy, their performance was not uniform. He says FIB-4, for example, performs less reliably in patients at extremes of age and in those with diabetes, and regional variability was observed, with weaker performance in South Asia and Latin America. In contrast, liver stiffness measurement was less affected by age or diabetes but was influenced by severe obesity. Among the available tools, AGILE 3 and AGILE 4 emerged as particularly stable across regions and subgroups.

Clinically, Younossi emphasizes a stepwise algorithm. FIB-4 remains the recommended first-line test to identify patients at low risk who can be monitored periodically versus those who warrant second-line assessment with VCTE or ELF. Beyond risk stratification, he says NITs now guide treatment selection, particularly for noncirrhotic MASH patients eligible for recently approved agents such as resmetirom or semaglutide and enable longitudinal monitoring.

Editors’ Note: Younossi reports relevant disclosures with Intercept, Cymabay, Boehringer Ingelheim, Ipsen, BMS, GSK, Novo Nordisk, Siemens, Madridgal, Merck, Aligos, Akero, Sanofi and Abbott.

Younossi ZM, de Avila L, Petta S, et al. Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study. 

. Published online January 28, 2026. doi:10.1016/j.cgh.2026.01.016

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed February 12, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed February 12, 2026. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Diagnostic Performance of NITs Across MASLD Subgroups, With Zobair Younossi, MD, MPH

Frank Gonzalez is an attending physician at Children’s Hospital Los Angeles and an assistant professor of clinical pediatrics at Keck School of Medicine of USC.

Managing Climate Change-Induced Sickle Cell Pain Crises With Frank Gonzalez, MD

Clinicians should be aware of the influence of extreme weather events on pain episodes in high risk pediatric patients with 

, according to an analysis of 48,885 emergency department visits.

 reported an independent association between extreme cold temperatures and increased vasocclusive episodes, as well as a suggested protective effect of extreme heat on acute chest syndrome.

The retrospective case-crossover study of weather-related emergency department encounters involved low risk and high risk patients 0 to 21 years of age at 40 US children’s hospitals.

In high risk patients, Gonzalez and colleagues observed elevated rates of emergency department visits for vasoocclusive crisis with increased temperature, heat index, and wet bulb globe temperature. In turn, with acute chest syndrome, these same variables were associated with decreased rates of visits. There were no significant associations in the low risk group.

“That allows you the opportunity to say, ‘Maybe last week there was a heat wave in the Los Angeles area, and we had patients coming in,’” study investigator Frank Gonzalez, MD, an attending physician in the emergency department at Children’s Hospital Los Angeles, told 

. “You can then make sure patients understand: try to stay hydrated, limit outdoor stress or exertional activity, and essentially create an environmental anticipatory guidance plan, an environmental care plan, to try to limit morbidity.”

Sickle cell disease itself sensitizes patients to cold and heat exposure. Often, the cold triggers vasoconstriction, reducing blood velocity, and increasing the likelihood of sickle-shaped red blood cells forming microvascular occlusions. On the other hand, hot temperatures lead to dehydration, increasing blood viscosity, raising the concentration of hemoglobin and sickle cells. These occlusions lead to local tissue hypoxia and ischemic pain similar to cold-induced crises.

While these environmental factors allowed investigators to glean insight into proactive clinical management strategies, Gonzalez believes there’s potential for a forecast-informed preventative model to prevent these complications from occurring beforehand, using the example of the Asthma Action Plan.

With the reality of climate change and the rising rates of extreme weather, there are other areas of environmentally related factors and sickle cell disease management left to be explored.

“Moving forward, one important area is wildfire-specific fine particulate matter or air pollution, related to wildfires and air pollution in general,” said Gonzalez. “Another important next step involves looking at multiple levels of risk factors, including patient-level or individual factors that could add to a patient’s vulnerability to environmental stressors.”

Gonzalez F, Hall M, Habre R, et al. Weather-Related Exposures and Emergency Department Visits for Pediatric Sickle Cell Complications. 

. Published online 2026:10.1097/PEC.0000000000003561. doi:

https://doi.org/10.1097/PEC.0000000000003561

Brandow AM, Stucky CL, Hillery CA, Hoffmann RG, Panepinto JA. Patients with sickle cell disease have increased sensitivity to cold and heat. 

Gonzalez explains how new findings in weather-related emergency department visits and pain in pediatric sickle cell disease can guide clinicians. 


Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

David Rizik, MD, is an interventional cardiologist at Banner University Health.

Rizik and Morris discuss the Heartflow PCI Navigator, which analyzes CT scans to generate 3D models of calcium blockages ahead of procedures.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Banner Health Debuts AI 3D Vascular Modeling Device, With David Rizik, MD, and Michael Morris, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

In this Q&A, investigators Maria Byazrova and Rudolf Valenta discuss findings on plasmablast's role in seasonal IgE surge when it comes to birch allergy.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Seasonal IgE Surge in Birch Allergy Driven by IgE⁺ Plasmablasts: Q&A With Investigators

The data represent the highest and most significant improvement in AHV and the first statistically significant improvement in body proportionality in achondroplasia.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial

Ashfaq Marghoob, MD, is a dermatologist specializing in the diagnosis and treatment of cancers of the skin and the director of the Memorial Sloan-Kettering regional skin cancer clinic.

In this Q&A segment of his interview, Marghoob speaks on-site at Maui Derm on tips related to dermoscopy and skin cancer detection.

Discussing Pediatric Dermoscopy and AI for Skin Cancer Detection, With Ashfaq Marghoob, MD

Desai discusses his recent observational cohort study indicating finerenone’s substantial reduction of heart failure exacerbation risk in patients with HFpEF.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Finerenone Outperforms Spironolactone for Heart Failure Exacerbation in HFpEF, With Nihar Desai, MD, MPH

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The American Society of Hematology released new 2026 Guidelines for Management of Relapsed/Refractory ALL in AYAs, discussing immunotherapy and personalized decision making. 


ASH Releases 8 Recommendations for Relapsed, Refractory Acute Lymphoblastic Leukemia in Adolescents, Young Adults

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

Tips on Dermoscopy and Skin Cancer Detection, With Ashfaq Marghoob, MD

Jonggi Choi, MD, PhD, is an associate professor at Asan Medical Center, University of Ulsan College of Medicine, and visiting scholar at Mass General Hospital.

Choi explains longstanding hesitancy around statin use in chronic liver disease, particularly cholestatic diseases like PBC, and how his research challenges these sentiments.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Shifting the Clinical Conversation Around Statins in PBC, With Jonggi Choi, MD, PhD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

From Inhalers to Immunology: Real-World Insights on Biologics in Asthma and COPD

Zhiyuan Wu, PhD, is a postdoctoral research fellow at the Harvard T.H. Chan School of Public Health.

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Latest News

Tool Predicts a 6-Year-Risk Lung Cancer Risk in Minutes, With Jessica Moffatt, PhD

Real-World Prescribing Patterns of PERT in Exocrine Pancreatic Insufficiency

Strategies on Maximizing Billing Effectiveness for Clinicians, With Mark Kaufmann, MD

Diagnostic Performance of NITs Across MASLD Subgroups, With Zobair Younossi, MD, MPH

Managing Climate Change-Induced Sickle Cell Pain Crises With Frank Gonzalez, MD